Figure 5.
Relationship between MR and disease activity. (A) The changes in DAS28-ESR during the follow-up period, which was split into two-week intervals. For each group, the average ± standard error of DAS28-ESR within the same interval was shown by the line. (B) Comparison of AUC (commutative DAS28-ESR during the 12-month follow-up) according to drug type. ‘*’: p < 0.05. AUC, area under the curve; DAS28-ESR, disease activity score-28 ESR; IFX, infliximab; MTX, methotrexate; TCZ, tocilizumab.